Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 10, 2010, Pages 3448-3456

  Ling, Yong ^a   Ye, Xiaolei ^a   Ji, Hui ^a   Zhang, Yihua ^a   Lai, Yisheng ^a   Peng, Sixun ^a   Tian, Jide ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti tumor agents; Cytotoxic activities; Farnesylthiosalicylic acid; Furoxans; NO donor; NO releasing; Ras related signaling

Indexed keywords

3 (PHENYLSULFONYL) 4 [2 [2 [1 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZOYL]PYRROLIDINE 2 CARBONYLOXY]ETHOXY]ETHOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [2 [2 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]ACETOXY]ETHOXY]ETHOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [2 [2 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]ETHOXY]ETHOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [3 [1 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZOY]PYRROLIDINE 2 CARBONYLOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [3 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]ACETOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [3 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [4 [1 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZOYL]PYRROLIDINE 2 CARBONYLOXY]BUT 2 YNYLOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [4 [1 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZOYL]PYRROLIDINE 2 CARBONYLOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [4 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]ACETOXY]BUT 2 YNYLOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 (PHENYLSULFONYL) 4 [4 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]BUT 2 YNYLOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 3 [4 [3 PHENYL 2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]BUTOXY] 4 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 (PHENYLSULFONYL) 3 [4 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]ACETOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 4 (PHENYLSULFONYL) 3 [4 [2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]BUTOXY] 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [2 [3 PHENYL 2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]ETHOXY]ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [3 [3 PHENYL 2 [2 (3,7,11 TRIMETHYLDOD ECA 2,6,10 TRIENYLTHIO)BENZAMIDO] PROPANOYLOXY]BUTOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [4 [3 PHENYL 2 [2 (3,7,11 TRIMETHYLDODECA 2,6,10 TRIENYLTHIO)BENZAMIDO]PROPANOYLOXY]BUT 2 YNYLOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; ANTINEOPLASTIC AGENT; FARNESYLTHIOSALICYLIC ACID; FURAZOLIDONE; HEMOGLOBIN; NITRIC OXIDE; RAS PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; FARNESOL; GENES, RAS; HUMANS; NITRIC OXIDE; OXADIAZOLES; SALICYLIC ACIDS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953138517     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.03.077     Document Type: Article

References (26)

1. Maity A., Pore N., Lee J., Solomon D., and O'Rourke D.M. Cancer Res. 60 (2000) 5879
2. Porfiri E., and McCormick F. J. Biol. Chem. 271 (1996) 5871
3. Boguski M.S., and McCormick F. Nature 366 (1993) 643
4. Goldberg L., and Kloog Y. Cancer Res. 66 (2006) 11709
5. Joneson T., White M.A., Wigler M.H., and Bar-Sagi D. Science 271 (1996) 810
6. Walsh A.B., and Bar-Sagi D. J. Biol. Chem. 276 (2001) 15609
7. Downward J. Curr. Opin. Genet. Dev. 8 (1998) 49
8. Bos J.L. Cancer Res. 49 (1989) 4682
9. Elad-Sfadia G., Haklai R., Ballan E., Gabius H.J., and Kloog Y. J. Biol. Chem. 277 (2002) 37169
10. Rotblat B., Niv H., Andre S., Kaltner H., Gabius H.J., and Kloog Y. Cancer Res. 64 (2004) 3112
11. Haklai R., Elad-Sfadia G., Egozi Y., and Kloog Y. Cancer Chemother. Pharmacol. 61 (2008) 89
12. Tsimberidou A.M., Rudek M.A., Hong D., Ng C.S., Blair J., Goldsweig H., and Kurzrock R. Cancer Chemother. Pharmacol. (2009) 10.1007/s00280-009-1027-4
13. Zundelevich A., Elad-Sfadia G., Haklai R., and Kloog Y. Mol. Cancer Ther. 6 (2007) 1765
14. Ignarro L.J. Biochem. Pharmacol. 41 (1991) 485
15. Fukuto J.M., and Wink D.A. Met. Ions Biol. Syst. 36 (1999) 547
16. Millet A., Bettaieb A., Renaud F., Prevotat L., Hammann A., Solary E., Mignotte B., and Jeannin J.F. Gastroenterology 123 (2002) 235
17. Postovit L.M., Adams M.A., Lash G.E., Heaton J.P., and Graham C.H. Int. J. Cancer 108 (2004) 47
18. Chen L., Zhang Y., Kong X., Lan E., Huang Z., Peng S., Kaufman D.L., and Tian J. J. Med. Chem. 51 (2008) 4834
19. Dhar A., Brindley J.M., Stark C., Citro M.L., Keefer L.K., and Colburn N.H. Mol. Cancer Ther. 2 (2003) 1285
20. Maksimovic-Ivanic D., Mijatovic S., Harhaji L., Miljkovic D., Dabideen D., Fan Cheng K., Mangano K., Malaponte G., Al-Abed Y., Libra M., Garotta G., Nicoletti F., and Stosic-Grujicic S. Mol. Cancer Ther. 7 (2008) 510
21. Moharram S., Zhou A., Wiebe L.I., and Knaus E.E. J. Med. Chem. 47 (2004) 1840
22. Killian D.M., Hermeling S., and Chikhale P.J. Drug Deliv. 14 (2007) 25
23. Yue W., Wang J., Li Y., Fan P., and Santen R.J. Int. J. Cancer 117 (2005) 746
24. Marra M., Lombardi A., Agostinelli E., Giuberti G., Zappavigna S., Tempera G., Vitale G., Bifulco M., Abbruzzese A., and Caraglia M. Biochim. Bioph. Acta 1783 (2008) 2269
25. Azuse I., Tamura M., Kinomura K., Okai H., Kouge K., Hamatsu F., and Koizumi T. Bull. Chem. Soc. Jpn. 62 (1989) 3103
26. Kong X., Zhang Y., Dai L., Lai Y., Ji H., and Peng S. Chin. Chem. Lett. 19 (2008) 149